These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27423481)

  • 21. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
    Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
    Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NS5A--from obscurity to new target for HCV therapy.
    Schmitz U; Tan SL
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of indole derivatives as novel hepatitis C virus inhibitors.
    Han Z; Liang X; Wang Y; Qing J; Cao L; Shang L; Yin Z
    Eur J Med Chem; 2016 Jun; 116():147-155. PubMed ID: 27061978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.
    Ramsis TM; Abdel Karim SE; Vassilaki N; Frakolaki E; Kamal AAM; Zoidis G; Ahmed NS; Abadi AH
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1800017. PubMed ID: 29799645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.
    Ding M; He F; Hudyma TW; Zheng X; Poss MA; Kadow JF; Beno BR; Rigat KL; Wang YK; Fridell RA; Lemm JA; Qiu D; Liu M; Voss S; Pelosi LA; Roberts SB; Gao M; Knipe J; Gentles RG
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2866-71. PubMed ID: 22424979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells.
    Hou W; Tian Q; Zheng J; Bonkovsky HL
    Gastroenterology; 2010 May; 138(5):1909-19. PubMed ID: 19909748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
    Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of hepatitis C virus NS5A inhibitors.
    Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
    J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.